The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …

Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection.
Precise characterization of clonal architecture is essential to understand the evolutionary …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Cancer relapse begins when malignant cells pass through the extreme metabolic bottleneck
of stress from chemotherapy and the byproducts of the massive cell death in the surrounding …

Based on the individual genetic profile, acute myeloid leukemia (AML) patients are classified
into clinically meaningful molecular subtypes. However, the mutational profile within these …

Acute myeloid leukaemia (AML) is a highly aggressive and devastating malignancy of the
bone marrow and blood. For decades, intensive chemotherapy has been the frontline …

In the era of precision medicine, liquid biopsy is becoming increasingly important in
oncology. It consists in the isolation and analysis of tumor-derived biomarkers, including …

High-throughput single-cell epigenomic assays can resolve cell type heterogeneity in
complex tissues, however, spatial orientation is lost. Here, we present single-cell …

Cancer development is an evolutionary genomic process with parallels to Darwinian
selection. It requires acquisition of multiple somatic mutations that collectively cause a …